Parexel to bring in 450 laid-off GSK employees in North Carolina

By Zachary Brennan

- Last updated on GMT

The deal to bring in GSK employees comes two years after the two forged a strategic partnership
The deal to bring in GSK employees comes two years after the two forged a strategic partnership

Related tags: North carolina

GlaxoSmithKline is significantly reducing the size of its R&D team in the US, though about 450 of those employees who will be laid off in the Research Triangle Park (RTP), North Carolina area will find new jobs with CRO Parexel.

GSK and Parexel have signed a letter of intent regarding the creation of a dedicated GSK business unit within Parexel​,” the company told us in an e-mailed statement.  “It will provide a variety of clinical development services and be largely based in the RTP area.  Under the agreement, approximately 450 employees currently working in R&D in RTP will be offered roles at Parexel​.” 

The cuts and transfers to Parexel are part of GSK’s restructuring, which will deliver approximately £1bn/$1.6 billion of new annual cost savings over the next three years across their global commercial operations, support functions, R&D and manufacturing units. There are about 2,500 GSK employees and contractors working in R&D in RTP.

In R&D, the majority of jobs affected are in Research Triangle Park (RTP), NC, as we consolidate our geographic footprint and locate the majority of our R&D organization into two major centers– in the Philadelphia area and Stevenage (UK)​,” a GSK spokeswoman told us.  “Some R&D roles will be relocated to the Philadelphia area and some staff will be offered relocation​.”  

Back in 2010, GSK selected Parexel as its strategic partner​, along with competitor PPD. The deals were part of a broader move by GSK to simplify clinical development and increase productivity. A GSK spokeswoman told us that this latest deal is an outgrowth of that previous collaboration.

The reduction of jobs in our US Pharmaceuticals business will affect employees in Philadelphia, RTP and the field​,” GSK said. “Retail sales teams focused on launching new medicines to the market will largely not be affected.  Our proposed changes to R&D will sharpen the focus in discovery and development and reduce funding in certain areas of the pipeline​.”

Parexel declined to comment on the latest letter of intent. 

Related news

Show more

Related products

show more

What’s Next for mRNA?

What’s Next for mRNA?

Catalent Pharma Solutions | 27-Jan-2022 | Insight Guide

Now that the pharma industry and regulators have significant data on safety and efficacy of mRNA vaccines, many companies are looking beyond infectious...

SmartSignals Study Oversight

SmartSignals Study Oversight

Signant Health | 24-Jan-2022 | Product Brochure

Today, sponsors and study teams often struggle to support the growing variety and volume of clinical data. The right technology thought will help your...

The APAC Advantages

The APAC Advantages

Catalent Pharma Solutions | 18-Jan-2022 | Insight Guide

Over recent years, the Asia-Pacific (APAC) region has become an emerging market for pharmaceutical and biotech innovation, including clinical studies.

CellCarta - Mapping Precision Medicine

CellCarta - Mapping Precision Medicine

CellCarta | 17-Jan-2022 | Product Presentation

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us

Products

View more

Webinars